Navarra, Spain – August 28, 2025 — Medibiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Novel Agonists of the PPAR-γ Receptor for the...
Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Continue their Support for the Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy...
Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain · The new facilities, of 200 square meters, consist of an office area next to a fully equipped medicinal...
Navarra – February 2025 – Medibiofarma S.L., a clinical-stage biotechnology company developinga portfolio of new small molecule therapies announced the award of the European CommissionSeal of Excellence...
Navarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced...
Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and...
Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment...
Navarra – December 2022 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases announced the first subject...
Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena (Public...